MA40254A - Polymorphes du selinexor - Google Patents
Polymorphes du selinexorInfo
- Publication number
- MA40254A MA40254A MA040254A MA40254A MA40254A MA 40254 A MA40254 A MA 40254A MA 040254 A MA040254 A MA 040254A MA 40254 A MA40254 A MA 40254A MA 40254 A MA40254 A MA 40254A
- Authority
- MA
- Morocco
- Prior art keywords
- selinexor
- polymorphs
- selinexor polymorphs
- Prior art date
Links
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 title 1
- 229950010613 selinexor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462038069P | 2014-08-15 | 2014-08-15 | |
| PCT/US2015/045395 WO2016025904A1 (fr) | 2014-08-15 | 2015-08-14 | Formes polymorphes de selinexor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40254A true MA40254A (fr) | 2021-05-19 |
| MA40254B1 MA40254B1 (fr) | 2022-09-30 |
Family
ID=53969460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40254A MA40254B1 (fr) | 2014-08-15 | 2015-08-14 | Polymorphes du selinexor |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US10519139B2 (fr) |
| EP (2) | EP3180331B1 (fr) |
| JP (3) | JP6777626B2 (fr) |
| KR (1) | KR102608259B1 (fr) |
| CN (3) | CN107072992B (fr) |
| AU (4) | AU2015301484B2 (fr) |
| CA (1) | CA2957266A1 (fr) |
| CO (1) | CO2017001884A2 (fr) |
| DK (1) | DK3180331T3 (fr) |
| EA (1) | EA201790384A1 (fr) |
| ES (1) | ES2926377T3 (fr) |
| IL (1) | IL250328B (fr) |
| MA (1) | MA40254B1 (fr) |
| MX (2) | MX388170B (fr) |
| SG (2) | SG10201808624VA (fr) |
| UA (1) | UA123535C2 (fr) |
| WO (1) | WO2016025904A1 (fr) |
| ZA (1) | ZA201700880B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4234545A3 (fr) | 2011-07-29 | 2023-09-06 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations |
| WO2013170068A2 (fr) | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Modulateurs du transport nucléaire et leurs utilisations |
| EP2968278B8 (fr) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1 |
| ME03421B (fr) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoles en tant que modulateurs de transport nucléaire et leurs utilisations |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| EP3397634A1 (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| WO2017118940A1 (fr) | 2016-01-08 | 2017-07-13 | Dr. Reddy's Laboratories Limited | Formes solides de sélinexor et leur procédé de préparation |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| EP3565813A1 (fr) | 2017-01-05 | 2019-11-13 | Watson Laboratories, Inc. | Nouvelles formes cristallines de sélinexor et leur procédé de préparation |
| CN106831731B (zh) * | 2017-01-17 | 2019-11-08 | 广州市闻皓生物科技有限公司 | 一种Selinexor原料药的合成方法 |
| WO2019232724A1 (fr) | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Composés en tant que modulateurs de transport nucléaire et leurs utilisations |
| WO2020072008A1 (fr) * | 2018-10-04 | 2020-04-09 | Deva Holding Anonim Sirketi | Nouvelles dispersions solides de sélinexor |
| BR112021016762A2 (pt) | 2019-03-20 | 2021-10-19 | Johnson Matthey Public Limited Company | Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor |
| CN114040909B (zh) | 2019-05-01 | 2025-06-03 | 卡尔约药物治疗公司 | 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法 |
| WO2020232439A1 (fr) * | 2019-05-16 | 2020-11-19 | Mayo Foundation For Medical Education And Research | Méthodes et substances pour le traitement du cancer |
| EP3808742A1 (fr) | 2019-10-16 | 2021-04-21 | Sandoz AG | Polymorphe de selinexor |
| WO2022087218A1 (fr) | 2020-10-21 | 2022-04-28 | Karyopharm Therapeutics Inc. | Forme cristalline de sélinexor |
| CN112679477B (zh) * | 2020-12-17 | 2021-10-26 | 佛山奕安赛医药科技有限公司 | 塞利尼索及其中间体的制备方法 |
| WO2023122014A1 (fr) * | 2021-12-20 | 2023-06-29 | Raytheon Technologies Corporation | Amélioration de particules de composites à matrice céramique, son procédé de fabrication et articles la comprenant |
| CN116675677B (zh) * | 2023-08-02 | 2023-09-26 | 中国林业科学研究院林产化学工业研究所 | 一种c8漆酚衍生物及其制备方法和应用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017398A (en) | 1911-01-16 | 1912-02-13 | John E Folsom | Telegraph-key. |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5468353A (en) | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
| EP0793653A1 (fr) | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Certains derives 4-aminomethyl 2-substitues de l'imidazole et derives 2-aminomethyl 4-substitues de l'imidazole, nouvelles categories de ligands specifiques du sous-type du recepteur de la dopamine |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| DE69736775T2 (de) | 1996-04-04 | 2007-08-23 | Shionogi & Co., Ltd. | Cephemverbindungen und medikamente die diese verbindungen enthalten |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| AU736854B2 (en) | 1996-04-25 | 2001-08-02 | Nissan Chemical Industries Ltd. | Ethylene derivatives and pesticides containing said derivatives |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| AU2960599A (en) | 1998-03-30 | 1999-10-18 | Akira Karasawa | Quinazoline derivatives |
| US6743585B2 (en) | 1999-09-16 | 2004-06-01 | Agilent Technologies, Inc. | Methods for preparing conjugates |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| EP1335898B1 (fr) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Composes d'acide carbamique comprenant un enchainement amide comme inhibiteurs hdac |
| CN101851173A (zh) * | 2001-09-14 | 2010-10-06 | 梅特希尔基因公司 | 组蛋白脱乙酰化酶抑制剂 |
| AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| AU2003278600A1 (en) | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| EP1599447A1 (fr) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands modulant des recepteurs du type lxr |
| RU2361872C2 (ru) | 2004-05-26 | 2009-07-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Циннамидное соединение |
| AU2005272389B2 (en) | 2004-08-11 | 2011-08-04 | Kyorin Pharmaceutical Co., Ltd. | Novel cyclic aminobenzoic acid derivative |
| WO2006019020A1 (fr) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | Urées de substitution |
| WO2006088246A1 (fr) | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Agent de controle de la fonction du recepteur gpr34 |
| PL1954684T3 (pl) * | 2005-11-15 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek oksazolowy i kompozycja farmaceutyczna |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| AR059955A1 (es) | 2006-03-09 | 2008-05-14 | Eisai R&D Man Co Ltd | Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide |
| CN101466670B (zh) | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| KR101130380B1 (ko) | 2006-06-13 | 2012-04-23 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도 |
| AU2007277519B2 (en) | 2006-07-27 | 2011-12-22 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| TWI386405B (zh) | 2006-09-05 | 2013-02-21 | 咪唑衍生物 | |
| EP1939180A1 (fr) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale |
| EP1942104A1 (fr) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique |
| WO2008106047A2 (fr) | 2007-02-26 | 2008-09-04 | Kosan Biosciences Incorporated | Composés de carbamate |
| EP2003118A1 (fr) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2 |
| WO2010017545A2 (fr) | 2008-08-08 | 2010-02-11 | Synta Pharamceuticals Corp. | Composés de triazole qui modulent l'activité hsp90 |
| JP2012532889A (ja) | 2009-07-09 | 2012-12-20 | クレッシェンド セラピューティクス、エルエルシー | 創傷治療方法及び傷跡変性方法 |
| US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| EP2542089B1 (fr) | 2010-03-05 | 2017-01-18 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| EP2665362B1 (fr) | 2011-01-17 | 2016-03-30 | Karyopharm Therapeutics, Inc. | Modulateurs du transport nucléaire contenant des oléfines et leurs utilisations |
| EP4234545A3 (fr) * | 2011-07-29 | 2023-09-06 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| WO2013020024A2 (fr) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Composés de maléimide et méthodes de traitement |
| WO2013170068A2 (fr) | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Modulateurs du transport nucléaire et leurs utilisations |
| EP2968278B8 (fr) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1 |
| WO2014152263A1 (fr) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire contenant une exo-oléfine et leurs utilisations |
| WO2014205393A1 (fr) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| ME03421B (fr) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoles en tant que modulateurs de transport nucléaire et leurs utilisations |
| US11567063B2 (en) * | 2013-11-15 | 2023-01-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods for assessing cell viability or predicting cell response to a treatment using cell movement |
| CN107209187B (zh) | 2014-07-11 | 2021-04-20 | 国立健康与医学研究所 | 用于诊断血液癌症的方法 |
| CN105294682B (zh) * | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| CN108348547B (zh) | 2015-08-28 | 2023-09-22 | 纽约市哥伦比亚大学信托人 | 用于匹配肿瘤学特征的系统和方法 |
| EP3397634A1 (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017118940A1 (fr) | 2016-01-08 | 2017-07-13 | Dr. Reddy's Laboratories Limited | Formes solides de sélinexor et leur procédé de préparation |
| JP6765198B2 (ja) | 2016-03-10 | 2020-10-07 | パナソニック株式会社 | 潜熱蓄熱材及びそれを用いる蓄熱システム |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| EP3565813A1 (fr) * | 2017-01-05 | 2019-11-13 | Watson Laboratories, Inc. | Nouvelles formes cristallines de sélinexor et leur procédé de préparation |
| CN106831731B (zh) | 2017-01-17 | 2019-11-08 | 广州市闻皓生物科技有限公司 | 一种Selinexor原料药的合成方法 |
| CA3131720A1 (fr) | 2019-03-27 | 2020-10-01 | Andrea Califano | Biomarqueurs du selinexor |
| EP3808742A1 (fr) | 2019-10-16 | 2021-04-21 | Sandoz AG | Polymorphe de selinexor |
| GB2591846B (en) | 2019-12-06 | 2024-08-14 | Bae Systems Plc | Light source |
| WO2022087218A1 (fr) | 2020-10-21 | 2022-04-28 | Karyopharm Therapeutics Inc. | Forme cristalline de sélinexor |
-
2015
- 2015-08-14 KR KR1020177006680A patent/KR102608259B1/ko active Active
- 2015-08-14 EP EP15754099.8A patent/EP3180331B1/fr active Active
- 2015-08-14 SG SG10201808624VA patent/SG10201808624VA/en unknown
- 2015-08-14 DK DK15754099.8T patent/DK3180331T3/da active
- 2015-08-14 EA EA201790384A patent/EA201790384A1/ru unknown
- 2015-08-14 MX MX2017002013A patent/MX388170B/es unknown
- 2015-08-14 WO PCT/US2015/045395 patent/WO2016025904A1/fr not_active Ceased
- 2015-08-14 CA CA2957266A patent/CA2957266A1/fr active Pending
- 2015-08-14 CN CN201580056017.1A patent/CN107072992B/zh active Active
- 2015-08-14 ES ES15754099T patent/ES2926377T3/es active Active
- 2015-08-14 UA UAA201702169A patent/UA123535C2/uk unknown
- 2015-08-14 AU AU2015301484A patent/AU2015301484B2/en active Active
- 2015-08-14 JP JP2017508087A patent/JP6777626B2/ja active Active
- 2015-08-14 MA MA40254A patent/MA40254B1/fr unknown
- 2015-08-14 US US15/503,319 patent/US10519139B2/en active Active
- 2015-08-14 SG SG11201700789SA patent/SG11201700789SA/en unknown
- 2015-08-14 CN CN202010093491.4A patent/CN111484483B/zh active Active
- 2015-08-14 CN CN202010093239.3A patent/CN111481553B/zh active Active
- 2015-08-14 EP EP22176543.1A patent/EP4112615A1/fr active Pending
-
2017
- 2017-01-29 IL IL250328A patent/IL250328B/en unknown
- 2017-02-03 ZA ZA2017/00880A patent/ZA201700880B/en unknown
- 2017-02-14 MX MX2021014128A patent/MX2021014128A/es unknown
- 2017-02-24 CO CONC2017/0001884A patent/CO2017001884A2/es unknown
-
2019
- 2019-11-11 US US16/679,630 patent/US11078190B2/en active Active
-
2020
- 2020-05-19 AU AU2020203246A patent/AU2020203246B2/en active Active
- 2020-05-29 JP JP2020093874A patent/JP7218323B2/ja active Active
-
2021
- 2021-07-01 US US17/365,656 patent/US11807629B2/en active Active
- 2021-12-14 AU AU2021286266A patent/AU2021286266B2/en active Active
-
2023
- 2023-01-25 JP JP2023009361A patent/JP7558310B2/ja active Active
- 2023-04-05 US US18/131,273 patent/US11753401B2/en active Active
- 2023-04-07 US US18/132,241 patent/US11746102B2/en active Active
- 2023-07-26 US US18/226,570 patent/US12371420B2/en active Active
-
2024
- 2024-04-30 AU AU2024202835A patent/AU2024202835A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301352I2 (nl) | epcoritamab | |
| NL301246I1 (nl) | Glofitamab | |
| NL301172I1 (nl) | Lonapegsomatropine | |
| MA40254A (fr) | Polymorphes du selinexor | |
| DK3183051T3 (da) | Væske-til-luftmembranenergivekslere | |
| LT3134402T (lt) | 4-amino-imidazochinolino junginiai | |
| DK3211743T3 (da) | Ø-til-netværk-omskiftningsfremgangsmåde | |
| FIC20265009I1 (fi) | Brensocatib | |
| DK3006072T3 (da) | Karadgang | |
| DK3222714T3 (da) | Phytasemutanter | |
| DK3119396T3 (da) | Muscarinreceptoragonister | |
| EP3230438C0 (fr) | N-glycosylation | |
| EP4011484C0 (fr) | Anhydrase carbonique de thermovibrio ammonificans | |
| DK4242916T3 (da) | Forstøver | |
| DK3183340T3 (da) | Termolabile exonukleaser | |
| DE112015001664A5 (de) | Betätigungsaktuator | |
| DK3154703T3 (da) | Fuldkappe-snekkecentrifuge | |
| FR3025617B1 (fr) | Architecture bi-voies | |
| DE112015005041A5 (de) | Gargerätevorrichtung | |
| DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
| DK3110439T3 (da) | Pcsk9-vacciner | |
| DE102014000623A8 (de) | Halbhohlnietelement | |
| DK3009858T3 (da) | Skyradar | |
| DE202014005655U8 (de) | llluminationsvorrichtung | |
| BR112016027901A2 (pt) | Compostos |